What is claimed is:

1. A method for treating or preventing a disease, comprising modulating the expression, function or activity of more than one protein kinase, comprising administering to a patient in need thereof an effective amount of the compound of having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each

of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

2. The method of claim 1 wherein A is a direct bond.

3. The method of claim 1 wherein R_1 is aryl optionally substituted with one to four substituents independently selected from R_3.

4. The method of claim 1 wherein R_1 is heteroaryl optionally substituted with one to four substituents independently selected from R_3.

5. The method of claim 1 wherein R_4 is substituted heterocycle.

6. The method of claim 1 wherein R_4 is 3-triazolyl, optionally substituted at its 5-position with:
(a) a C_1-C_4 straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
(b) a 2-pyrrolidinyl group.

7. The method of claim 1, wherein -A-R_1 is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, $-NR_8C(=O)R_9$, $-C(=O)NR_8R_9$, and $-O(CH_2)_bNR_8R_9$, wherein *b* is 2 or 3.

8. The method of claim 1, wherein the protein kinase is a protein tyrosine kinase.

9. The method of claim 1, wherein the expression, function or activity of the protein kinases are simultaneously modulated.

10. The method of claim 9, wherein the expression, function or activity of the protein kinases are simultaneously inhibited.

11. The method of claim 1, wherein the protein kinase is Aurora-A, AKT, CDK1/cyclinB(h), CDK2/cyclinA(h), CDK3/cyclinE(h), CDK5/p35(h), CDK6/cyclinD3(h), CDK7/cyclinH/MAT1, CHK1, CHK2, EGFR, c-RAF, RAS, cSRC, Yes, Fyn, Lck, Fes, Lyn, Syk, Bmx, FGFR3, GSK3α, GSK3ß, PI3, IGF-1R, MAPK2, MAPKAP-K2, JNK, MEK1, p70S6K, PAK2, PDGFRα, PDGFRß, PDK1, PKA, PKCϵ, PKCμ, PKD2, VEGF, PRAK, PRK2, ROCK-II, Rsk1, Rsk2, Rsk3 or SGK.

12. The method of claim 8, wherein the a expression, function or activity of the protein tyrosine kinases are selectively inhibited over non-tyrosine kinases.

13. The method of claim 1, wherein the expression, function or activity of Auroa-A, Blk, CDK1, CDK2, CDK3, CDK5, CDK6, CHK1, CHK2, Src family of kinases, cSrc, Yes, Fyn, Lck, Fes, , Lyn, Syk, , FGF-R3, GSK3a, GSK3b, MAPK family including JNK, MEK, p70S6K, PKCmu, PKD2, PRAK, PRK2, ROCK-II, RSK1, RSK2 and RSK3 are selectively modulated over other kinases.

14. The method of claim 13, wherein the modulation is inhibition.

15. The method of claim 1, wherein the disease is an anti-proliferative disease.

16. The method of claim 15, wherein the anti-proliferative disease is cancer.

17. The method of claim 16, wherein the cancer is of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system

18. The method of claim 1, wherein the disease is an inflammatory disease.

19. The method of claim 18, wherein the inflammatory disease is hereditary obesity, dietary obesity, hormone related obesity, obesity related to the administration of medication, Type I diabetes, diabetes insipidus, diabetes mellitus, maturity-onset diabetes, juvenile diabetes, insulin-dependant diabetes, non-insulin dependant diabetes, malnutrition-related

diabetes, ketosis-prone diabetes, ketosis-resistant diabetes, hearing loss, otitis externa, acute otitis media, chronic obstructive pulmonary disease, pulmonary interstitial fibrosis, acute respiratory distress syndrome, renal fibrosis, liver fibrosis, cystic fibrosis, wound-healing, burn-healing, allergy, allergic rhinitis, systemic lupus erythematosus, nephropathy, pancreatitis, peritonitis or ischemia-reperfusion injury.

20. The method of claim 1, wherein the disease is a liver disease.

21. The method of claim 20, wherein the liver disease is hepatitis, alcohol-induced liver disease, toxin-induced liver disease, steatosis or sclerosis.

22. The method of claim 1, wherein the disease is a cardiovascular disease.

23. The method of claim 22, wherein the cardiovascular disease is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, myocardial infarction, chronic obstructive pulmonary disease or stroke.

24. The method of claim 1, wherein the disease is a neurodegenerative disease.

25. The method of claim 24, wherein the neurodegenerative disease is epilepsy, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, peripheral neuropathies, spinal cord damage, AIDS dementia complex or Parkinson's disease.